Generation of a novel proteolysis resistant vascular endothelial growth factor165 variant by a site‐directed mutation at the plasmin sensitive cleavage site

Vascular endothelial growth factor (VEGF) is a potent angiogenic mediator in tissue repair. In non‐healing human wounds plasmin cleaves and inactivates VEGF165. In the present study, we generated recombinant VEGF165 mutants resistant to plasmin proteolysis. Substitution of Arg110 with Ala110 or Gln110, and Ala111 with Pro111 yielded plasmin‐resistant and biologically active VEGF165 mutants. In addition, substitution of Ala111 with Pro111 resulted in a substantial degree of stabilization when incubated in wound fluid obtained from non‐healing wounds. These results suggest that the plasmin cleavage site Arg110/Ala111 and the carboxyl‐terminal domain play an important role in the mitogenic activity of VEGF165.

[1]  M. Shibuya.  Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. , 2001, Cell structure and function.

[2]  P. Matsudaira,et al.  Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. , 1987, The Journal of biological chemistry.

[3]  A. Singer,et al.  Cutaneous wound healing. , 1999, The New England journal of medicine.

[4]  R. Burgeson,et al.  In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin. , 2000, The American journal of pathology.

[5]  C. Owen,et al.  Leukocyte proteinases in wound healing: roles in physiologic and pathologic processes , 1999, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[6]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[7]  M. Klagsbrun,et al.  Neuropilin is a Mediator of Angiogenesis , 2004, Cancer and Metastasis Reviews.

[8]  S. Soker,et al.  The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. , 1992, The Journal of biological chemistry.

[9]  M. Shibuya,et al.  A Novel Type of Vascular Endothelial Growth Factor, VEGF-E (NZ-7 VEGF), Preferentially Utilizes KDR/Flk-1 Receptor and Carries a Potent Mitotic Activity without Heparin-binding Domain* , 1998, The Journal of Biological Chemistry.

[10]  S. Soker,et al.  Selective Binding of VEGF to One of the Three Vascular Endothelial Growth Factor Receptors of Vascular Endothelial Cells (*) , 1996, The Journal of Biological Chemistry.

[11]  H. Dvorak,et al.  Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing , 1992, The Journal of experimental medicine.

[12]  Sathyanarayana,et al.  Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. , 2001, The Journal of surgical research.

[13]  F. Bayard,et al.  Extracellular Cleavage of the Vascular Endothelial Growth Factor 189-Amino Acid Form by Urokinase Is Required for Its Mitogenic Effect* , 1997, The Journal of Biological Chemistry.

[14]  J. Park,et al.  The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. , 1993, Molecular biology of the cell.

[15]  K. Scharffetter-Kochanek,et al.  Protease inhibitors protect growth factor activity in chronic wounds , 1997, The British journal of dermatology.

[16]  B. Gilchrest,et al.  Workshop on the pathogenesis of chronic wounds. , 1994, The Journal of investigative dermatology.

[17]  F. Grinnell,et al.  Degradation of fibronectin and vitronectin in chronic wound fluid: analysis by cell blotting, immunoblotting, and cell adhesion assays. , 1992, The Journal of investigative dermatology.

[18]  B. Keyt,et al.  Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors , 1996, The Journal of Biological Chemistry.

[19]  Shay Soker,et al.  Neuropilin-1 Is Expressed by Endothelial and Tumor Cells as an Isoform-Specific Receptor for Vascular Endothelial Growth Factor , 1998, Cell.

[20]  Hung V. Nguyen,et al.  The Carboxyl-terminal Domain(111165) of Vascular Endothelial Growth Factor Is Critical for Its Mitogenic Potency (*) , 1996, The Journal of Biological Chemistry.

[21]  T. Krieg,et al.  Expression and proteolysis of vascular endothelial growth factor is increased in chronic wounds. , 2000, The Journal of investigative dermatology.

[22]  H. Augustin,et al.  A novel vascular endothelial growth factor encoded by Orf virus, VEGF‐E, mediates angiogenesis via signalling through VEGFR‐2 (KDR) but not VEGFR‐1 (Flt‐1) receptor tyrosine kinases , 1999, The EMBO journal.

[23]  J. Winer,et al.  Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. , 1992, The Journal of biological chemistry.

[24]  M. Shibuya,et al.  A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. , 1995, Oncogene.

[25]  M. Shibuya,et al.  Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. , 1994, The Journal of biological chemistry.

[26]  D. Hicklin,et al.  Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. , 1994, The Journal of biological chemistry.